Clinical Trials Logo
  1. Home
  2. Asthma
  3. NCT01690793
  4. Details
NCT01690793 Clinical Trial

Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma

ASTHMA Clinical Trial

— acute asthma  

Official title:
Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01690793
Other study ID # acute asthma
Secondary ID
Status Completed
Phase N/A
First received August 5, 2010
Last updated May 27, 2015
Start date February 2009
Est. completion date February 2011

Study information
Verified date May 2015
Source University of South Florida
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The investigators hypothesize that there is a statistically significant decrease of Natriuretic Hormone Peptides (NHPs) in subjects with asthma exacerbation compared to levels following treatment of an exacerbation of asthma.

Description:

Overall Study Design

1. Measurement of Natriuretic Hormone Peptides in individuals suffering from exacerbation of asthma.

2. Measurement of Natriuretic Hormone Peptides 5-7 days after initiation of treatment of exacerbation of asthma.

3. Measurement of Natriuretic Hormone Peptides 10-14 days after initiation of treatment of exacerbation of asthma.

3 comparisons of Natriuretic Hormone Peptides levels will be made:

1. Exacerbation compared to 5-7 days after initiation of treatment

2. Exacerbation compared to 10-14 days after initiation of treatment

3. 5-7 days after initiation of treatment compared to 10-14 days after initiation of treatment.

Samples of blood will be secured in the Division of Allergy/Immunology at the University of South Florida, Joy McCann Culverhouse Airways Disease Center. All samples will be appropriately coded to maintain confidentiality. Blood specimens will be held at minus 20 degrees Celsius.

Recruitment information / eligibility
Status Completed
Enrollment 30
Est. completion date February 2011
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Both genders, age 18-85.

- Females who are pregnant or lactating are not eligible.

- Read and comprehend English.

- Ability to give informed consent.

- Seen in the outpatient setting at one of the clinic.

- The subject must have a history of physician diagnosed asthma for at least 1 year and must have an exacerbation of asthma for entry into the study.

Study Design

N/A

Related Conditions & MeSH terms

Locations
Country Name City State
United States Usf Asthma Allergy and Immunology Cru Tampa Florida

Sponsors (1)
Lead Sponsor Collaborator
University of South Florida

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary The measurement of NHPs after treatment of an exacerbation of asthma 14 days No
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device